Last €62.99 EUR
Change Today -0.447 / -0.70%
Volume 377.0
As of 11:11 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/15 - €65.00
52 Week Low
04/8/14 - €40.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases, as well as controls intestinal parasite infections in dogs. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Announces Issuance and Sale of $600,000,000 Aggregate Principal Amount of its 1.250% Notes Due 2018

On February 24, 2015, Eli Lilly and Company entered into an Underwriting Agreement between the Company and Deutsche Bank Securities Inc., Goldman, Sachs & Co. and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein, for the issuance and sale by the Company of $600,000,000 aggregate principal amount of its 1.250% Notes due 2018, $800,000,000 aggregate principal amount of its 2.750% Notes due 2025 and $800,000,000 aggregate principal amount of its 3.700% Notes due 2045 (the 2045 Notes, and together with the 2018 Notes and the 2025 Notes, the Notes). The Notes are to be issued pursuant to an Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor to Citibank, N.A., as trustee, and an officer's certificate setting forth the terms of the Notes. The offering of the Notes was registered on a Registration Statement on Form S-3 (File No. 333-186979). The 2018 Notes accrue interest at a rate of 1.250% per annum, payable semiannually, and mature on March 1, 2018. The 2025 Notes accrue interest at a rate of 2.750% per annum, payable semiannually, and mature on June 1, 2025. The 2045 Notes accrue interest at a rate of 3.700% per annum, payable semiannually, and mature on March 1, 2045. At the closing of the offering of Notes, which is expected to occur on March 5, 2015, the company will realize, after deduction of the underwriter's discount and before deduction of offering expenses, net proceeds of approximately $2,181,948,000.

Cerecor Purchases Rights from Eli Lilly to Develop LY2456302

Cerecor reported that it has acquired exclusive, worldwide rights from Eli Lilly and Company to develop and commercialize LY2456302, a Phase 2-ready, potent and selective kappa opioid receptor antagonist. KORs are believed to play a key role in modulating stress, mood and addictive disorders. Research also suggests that selective KOR antagonists can block both the physical and emotional symptoms of nicotine withdrawal. CERC-501 was discovered and developed by Lilly for the treatment of co-occurring disorders, defined as a patient having one or more disorders relating to substance abuse combined with one or more mental health disorders. In Phase 1 clinical studies, CERC-501 was well tolerated, penetrated the blood-brain barrier and demonstrated target engagement, as shown through PET (positron emission tomography) imaging.

Eli Lilly and Company Announces Update on Regulatory Submission Timing for Basal Insulin Peglispro

Eli Lilly and Company announced delay in the submission of basal insulin peglispro (BIL) to regulatory agencies beyond the first quarter of 2015. The delay includes filings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency. Lilly will delay submission in order to generate additional clinical data to further understand and characterize the potential effects, if any, of changes in liver fat observed with BIL treatment in the Phase III trials. Lilly intends that ongoing clinical trials will continue as planned. In the clinical development program to date, in which more than 6,000 patients with type 1 and type 2 diabetes were treated for up to 18 months (approximately 3,900 patients treated with BIL), no drug-induced liver impairment or Hy's Law cases have been observed. The length of the delay cannot be determined until clinical trial plans have been developed. However, the company anticipates the submission is likely to occur after 2016. Lilly is working to determine next steps, including potential consultations with regulators. Information regarding future submission timing will be provided following these activities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €62.99 EUR -0.447

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.09 USD -0.13
AbbVie Inc $59.62 USD -0.84
Actavis plc $296.23 USD -1.08
AstraZeneca PLC 4,432 GBp -44.00
Teva Pharmaceutical Industries Ltd $56.46 USD -0.70
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 31.5x
Price/Sales 3.8x
Price/Book 4.8x
Price/Cash Flow 32.6x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at